Apogee Therapeutics, Inc. APGE Proceeds From Issuance Of Common Stock Under At The Market Equity Offering Program Net Of Issuance Costs
Proceeds From Issuance Of Common Stock Under At The Market Equity Offering Program Net Of Issuance Costs at other companies
Other financials
Where this comes from
Reported directly by Apogee Therapeutics, Inc. in its filing.
Tagged under the XBRL concept apge:ProceedsFromIssuanceOfCommonStockUnderAtTheMarketEquityOfferingProgramNetOfIssuanceCosts.
The official record: Apogee Therapeutics, Inc.’s 10-K, filed March 2, 2026, on SEC EDGAR. View the filing →
Ask your AI about Apogee Therapeutics, Inc.'s proceeds from issuance of common stock under at the market equity offering program net of issuance costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Apogee Therapeutics, Inc.'s proceeds from issuance of common stock under at the market equity offering program net of issuance costs?
- Apogee Therapeutics, Inc. (APGE) reported proceeds from issuance of common stock under at the market equity offering program net of issuance costs of $16.4M in Q4 2025.
- How has Apogee Therapeutics, Inc.'s proceeds from issuance of common stock under at the market equity offering program net of issuance costs changed year-over-year?
- Apogee Therapeutics, Inc.'s proceeds from issuance of common stock under at the market equity offering program net of issuance costs increased by 50.7% year-over-year, from $10.88M to $16.4M.
- What does proceeds from issuance of common stock under at the market equity offering program net of issuance costs mean?
- This captures the cash proceeds received from selling shares incrementally into the secondary market at prevailing market prices, often referred to as an 'at-the-market' (ATM) offering. It provides companies with a flexible mechanism to raise capital without the need for a traditional, large-scale underwritten offering. Investors track this to evaluate the company's ongoing dilution strategy and its reliance on equity markets for liquidity.